Home › Major Depressive Disorder › NCT05922878
Study of ALTO-300 in MDD
RecruitingPhase 2
A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder
Who can join
Ages 18 to 70 · All sexes
Full eligibility criteria
Inclusion Criteria: * Have a diagnosis of moderate to severe major depressive disorder (MDD) * At Visit 1, currently taking a single SSRI, SNRI, or bupropion for at least 6 weeks with no dose modifications in the past 2 weeks by Visit 2 * Willing to comply with all study assessments and procedures * Must not be pregnant or breastfeeding at time of enrollment or throughout study Exclusion Criteria: * Evidence of unstable medical condition * Nightly use of sleep medication * Diagnosed bipolar disorder, psychotic disorder, or dementia * Current moderate or severe substance use disorder * Has a history of hypersensitivity or allergic reaction to ALTO-300 or any of its components/excipients * Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device
About the study
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
What is being tested
- ALTO-300 (drug)
- Placebo (drug)
Sponsor: Alto Neuroscience · Participants: 321 · Started: Jun 8, 2023
Contact the study team
- Alto Neuroscience · Phone: 650-200-0412
Official record on ClinicalTrials.gov — NCT05922878
Locations in the U.S.
| Arizona | Site 200, Phoenix Site 187, Yuma |
| Arkansas | Site 193, Rogers |
| California | Site 218, Bellflower Site 217, Glendale Site 335, Lafayette Site 209, Los Angeles Site 219, Mather Site 194, Mission Viejo Site 197, Temecula |
| Colorado | Site 203, Colorado Springs Site 349, Evergreen |
| Connecticut | Site 214, Norwalk |
| Florida | Site 159, Clermont Site 225, Miami Gardens Site 190, Miami Lakes Site 161, Okeechobee Site 221, Tampa Site 220, West Palm Beach |
| Georgia | Site 224, Savannah Site 208, Snellville |
| Idaho | Site 119, Boise |
| Illinois | Site 310, Chicago |
| Mississippi | Site 215, Jackson |
| Nevada | Site 344, Las Vegas |
| New Mexico | Site 114, Albuquerque |
| New York | Site 192, Staten Island |
| North Carolina | Site 199, Hickory |
| Ohio | Site 202, Cincinnati |
| Oklahoma | Site 195, Oklahoma City |
| Pennsylvania | Site 216, Allentown Site 350, Media Site 352, Moosic |
| Texas | Site 347, Fort Worth Site 353, Plano (Not yet recruiting) Site 196, Richmond |
| Utah | Site 207, Clinton |
| Virginia | Site 211, Roanoke |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.